Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Adjuvant chemotherapy and targeted therapies comprise two salient practice-changing improvements in the treatment of non-small-cell lung cancer. Despite the fact that these improvements have been largely data-driven, the following questions arise: what is the role of adjuvant chemotherapy in elderly patients with non-small-cell lung cancer? What is the role of targeted agents, such as erlotinib and bevacizumab, in older non-small-cell lung cancer patients? These questions are relevant because the current median age of lung cancer patients at diagnosis in the USA is 69 years, and the number of older patients developing this malignancy is increasing. This review provides guidance on how best to approach the use of adjuvant chemotherapy and targeted therapies in older patients with this disease.

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalAging Health
Volume8
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Therapeutics
Lung Neoplasms
Neoplasms

Keywords

  • adjuvant
  • chemotherapy
  • elderly
  • non-small-cell lung cancer
  • targeted therapy

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients. / Jatoi, Aminah.

In: Aging Health, Vol. 8, No. 3, 06.2012, p. 309-316.

Research output: Contribution to journalArticle

@article{7b29c79fc85a40c8b1df06ac5f859098,
title = "Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients",
abstract = "Adjuvant chemotherapy and targeted therapies comprise two salient practice-changing improvements in the treatment of non-small-cell lung cancer. Despite the fact that these improvements have been largely data-driven, the following questions arise: what is the role of adjuvant chemotherapy in elderly patients with non-small-cell lung cancer? What is the role of targeted agents, such as erlotinib and bevacizumab, in older non-small-cell lung cancer patients? These questions are relevant because the current median age of lung cancer patients at diagnosis in the USA is 69 years, and the number of older patients developing this malignancy is increasing. This review provides guidance on how best to approach the use of adjuvant chemotherapy and targeted therapies in older patients with this disease.",
keywords = "adjuvant, chemotherapy, elderly, non-small-cell lung cancer, targeted therapy",
author = "Aminah Jatoi",
year = "2012",
month = "6",
doi = "10.2217/ahe.12.29",
language = "English (US)",
volume = "8",
pages = "309--316",
journal = "Aging Health",
issn = "1745-509X",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Adjuvant chemotherapy and targeted therapy in elderly non-small-cell lung cancer patients

AU - Jatoi, Aminah

PY - 2012/6

Y1 - 2012/6

N2 - Adjuvant chemotherapy and targeted therapies comprise two salient practice-changing improvements in the treatment of non-small-cell lung cancer. Despite the fact that these improvements have been largely data-driven, the following questions arise: what is the role of adjuvant chemotherapy in elderly patients with non-small-cell lung cancer? What is the role of targeted agents, such as erlotinib and bevacizumab, in older non-small-cell lung cancer patients? These questions are relevant because the current median age of lung cancer patients at diagnosis in the USA is 69 years, and the number of older patients developing this malignancy is increasing. This review provides guidance on how best to approach the use of adjuvant chemotherapy and targeted therapies in older patients with this disease.

AB - Adjuvant chemotherapy and targeted therapies comprise two salient practice-changing improvements in the treatment of non-small-cell lung cancer. Despite the fact that these improvements have been largely data-driven, the following questions arise: what is the role of adjuvant chemotherapy in elderly patients with non-small-cell lung cancer? What is the role of targeted agents, such as erlotinib and bevacizumab, in older non-small-cell lung cancer patients? These questions are relevant because the current median age of lung cancer patients at diagnosis in the USA is 69 years, and the number of older patients developing this malignancy is increasing. This review provides guidance on how best to approach the use of adjuvant chemotherapy and targeted therapies in older patients with this disease.

KW - adjuvant

KW - chemotherapy

KW - elderly

KW - non-small-cell lung cancer

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84862876961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862876961&partnerID=8YFLogxK

U2 - 10.2217/ahe.12.29

DO - 10.2217/ahe.12.29

M3 - Article

AN - SCOPUS:84862876961

VL - 8

SP - 309

EP - 316

JO - Aging Health

JF - Aging Health

SN - 1745-509X

IS - 3

ER -